Insights with Goldman Sachs Part 4: The impact of the Inflation Reduction Act
How will the Inflation Reduction Act impact biopharma? What about the loss of patent exclusivity and its impact on product priorities? Will the increased scrutiny on M&A by the Federal Trade Commission slow down deal making? Hear what our panelists had to say on the topics, including Jerry Lee, Partner of Global Healthcare Investment Banking Group at Goldman Sachs and Lyla Bibi, Managing Director and Head of Americas Healthcare Equity Capital Markets at Goldman Sachs.
Disclaimer: The views and opinions that the panelists express are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs Asset Management for you to take any action.